Results 21 to 30 of about 89,537 (296)

JAK inhibition ameliorates bone destruction by simultaneously targeting mature osteoclasts and their precursors

Inflammation and Regeneration, 2023
Background Rheumatoid arthritis (RA) is characterized by chronic inflammation and resultant cartilage/bone destruction because of aberrantly activated osteoclasts.
Shinya Yari, Junichi Kikuta, Hotaka Shigyo, Yu Miyamoto, Daisuke Okuzaki, Yuki Furusawa, Masafumi Minoshima, Kazuya Kikuchi, Masaru Ishii   +8 more
doaj   +1 more source

Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss

Inflammation and Regeneration, 2023
Background The types of bone damage in rheumatoid arthritis (RA) include joint erosion, periarticular osteoporosis, and systemic osteoporosis. Janus kinase (JAK) inhibitors ameliorate inflammation and joint erosion in RA, but their effect on the three ...
Masatsugu Komagamine, Noriko Komatsu, Rui Ling, Kazuo Okamoto, Shi Tianshu, Kotaro Matsuda, Tsutomu Takeuchi, Yuko Kaneko, Hiroshi Takayanagi   +8 more
doaj   +1 more source

Insights, current status and future perspective of JAK inhibitors in the treatment of alopecia areata

Pifu-xingbing zhenliaoxue zazhi, 2022
Alopecia areata (AA) is a chronic heterogeneous inflammatory disease, with unknown pathogenesis. Although there are quite a few options to choose for treatment of AA, there is no specific therapic method, and neither is one therapic method for all ...
Xingqi ZHANG
doaj   +1 more source

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies

Immunological Medicine, 2023
Recent studies have demonstrated that Janus kinase (JAK) plays a crucial role in signal transduction by directly affecting various cytokine receptors involved in inflammatory diseases such as atopic dermatitis (AD).
Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima   +2 more
doaj   +1 more source

Network pharmacology of JAK inhibitors [PDF]

Proceedings of the National Academy of Sciences, 2016
SignificanceJAK kinase inhibitors (JAKis) have advanced options for treatment of autoimmune diseases. Because JAKs are signaling hubs for several cytokine receptors, JAKis’ overall impact on the immune system and how they actually improve diseases like rheumatoid arthritis remain poorly understood.
Devapregasan, Moodley, Hideyuki, Yoshida, Sara, Mostafavi, Natasha, Asinovski, Adriana, Ortiz-Lopez, Peter, Symanowicz, Jean-Baptiste, Telliez, Martin, Hegen, James D, Clark, Diane, Mathis, Christophe, Benoist   +10 more
openaire   +2 more sources

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

HemaSphere, 2023
The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF).
Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Miklos Egyed, Uwe Platzbecker, Jiří Mayer, Sebastian Grosicki, Árpád Illés, Tomasz Woźny, Stephen T. Oh, Donal McLornan, Ilya Kirgner, Sung-Soo Yoon, Claire N. Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben Mesa   +19 more
doaj   +1 more source

JAK inhibitors ∼ overview∼

Immunological Medicine, 2023
Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons. Indeed, recent rapid progress in JAK inhibitors in addition to biological agents provided therapeutic options for various diseases, including immune-mediated ...
openaire   +3 more sources

Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. [PDF]

, 2022
OBJECTIVES JAK Inhibitors (JAKi) are recommended DMARDs for patients with moderate-to severe rheumatoid arthritis (RA) who failed first-line therapy with methotrexate.
Mueller, Ruediger, Amstad, Andrea, Rubbert-Roth, Andrea, Finckh, Axel, Villiger, Peter M, Papagiannoulis, Eleftherios, Schulz, Martin M P, Kyburz, Diego, Scherer, Almut, Dudler, Jean, Möller, Burkhard   +10 more
core   +1 more source

JAK inhibitors and COVID-19

Journal for ImmunoTherapy of Cancer, 2022
During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked to ...
Levy, G, Guglielmelli, P, Langmuir, P, Constantinescu, S   +3 more
openaire   +6 more sources

Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling [PDF]

, 2010
Chikungunya virus (CHIKV) is an emerging human pathogen transmitted by mosquitoes. Like that of other alphaviruses, CHIKV replication causes general host shutoff, leading to severe cytopathicity in mammalian cells, and inhibits the ability of infected ...
Ligtenberg, M., Suhrbier, A., Corinne Geertsema, Esther Schnettler, Fros, J., Just M. Vlak, Maarten Ligtenberg, Geertsema, C., Suhrbier, Andreas, Wen Jun Liu, Natalie A. Prow, Vlak, J.M., Dana L. Vanlandingham, Ligtenberg, Maarten, Khromykh, Alexander A., Jelke J. Fros, Vanlandingham, D.L., Vlak, Just M., Schnettler, E., Fros, J.J., Gorben P. Pijlman, Pijlman, G.P., Liu, W.J., Khromykh, A.A., Prow, A., Fros, Jelke J., Vanlandingham, Dana L., Liu, Wen Jun, Geertsema, Corinne, Prow, Natalie A., Alexander A. Khromykh, Schnettler, Esther, Pijlman, Gorben P., Andreas Suhrbier, Prow, N.A.   +34 more
core   +1 more source